7 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Pneumocystis pneumonia (PCP ... Mycobacterium tuberculosis ... #OIs #HIVAIDS #IDSA ... #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Pneumocystis pneumonia (PCP ... Mycobacterium tuberculosis ... #OIs #HIVAIDS #IDSA ... #management #pharmacology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... Diagnosis: Latent ... staining, NAA (PCR ... #TB #Diagnosis ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... Diagnosis: Latent ... staining, NAA (PCR ... #TB #Diagnosis ... #Management #Treatment
C.diff - Clostridioides Difficile Infection (CDI) - Diagnosis and Management - GrepMed Handbook

Clinical Presentation + Progression:
and Management ... non-toxigenic • Stool PCR ... (IDSA 2021): ... treatment • Prophylaxis ... /severe CDI IDSA
IDSA Recommendations for Prevention and Treatment of Pneumocystis Pneumonia (PCP) in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
IDSA Recommendations ... Initiating Primary Prophylaxis ... Pneumocystis #Pneumonia #IDSA ... infections #HIVAIDS #management ... #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... for active or latent ... and molecular diagnostic ... #Treatment #management ... infections #HIVAIDS #pharmacology